Mateo SHA, Mateo SE, Hernández AL, Salazar REL

Language: Spanish
References: 12
Page: 141-146
PDF size: 93.70 Kb.

ABSTRACT

Statistics shows that polycystic ovary syndrome is a common syndrome affecting approximately 5-10% of women. Polycystic ovary syndrome (PCOS) is usually emotionally and physically exhausting for the women suffering it. Their desire to lose weight, continually making an effort, and finally not achieving it produce frustration and deception; on the other hand, the esthetic aspect worries women frequently, due to the excessive hair growth and acne. Ultimately, it is important to mention the fertility impact, which is one of the main medical consultation causes by PCOS. Treating the syndrome is not impossible, but it does have its complications due to the multiple factors that produce it. Studies show that hyperinsulinemia is the leading cause of most of biochemical alterations, so if they are treated a benefic effect is obtained. Metformin is the most used and studied antihyperglucemic drug in the market. Its impact on the physiopathology of the disease is overwhelming, improving androgen pathological biosynthesis, and therefore, improving ovarian functioning, which favors fertility.

REFERENCES

1. Fábregues F. Epidemiología y conceptos generales. En: Checa MA, Espinós JJ, Matorras R, editores. Síndrome de ovario poliquístico. Madrid: Panamericana, 2006;13-23.

2. American Society for Reproductive Medicine, Patient’s fact sheet. Polycystic ovary syndrome, 2005. Disponible en: http://www.asrm.org/uploadedFiles/ASRM_Content/Resources/Patient_Resources/Fact_Sheets_and_Info_Booklets/PCOS.pdf

3. Warren-Ulanch J, Arslanian S.A. Insulin action and secretion in polycystic ovary syndrome. In: Dunaif A, Chang RJ, Franks S, Legro RS, editors. Polycystic ovary syndrome: current controversies, from the ovary to the pancreas. Totowa NJ: Humana Press, 2008;159-183.

4. Archivo online de la American Society for Reproductive Medicine. Agentes sensibilizadores a la insulina y SOP. Disponible en: http://www.reproductivefacts.org/uploadedFiles/ASRM_Content/Resources/Patient_Resources/Fact_Sheets_and_Info_Booklets_en_Espanol/Agentes_sensibilizadores_a_la_insulina_y_SOP.pdf

5. Velásquez O, Lara A, Tapia R. Metformina y síndrome metabólico. Manual de uso. Estado de México: Secretaría de Salud, 2002;13-19.

6. Diccionario de Especialidades Farmacéuticas. Edición electrónica 55. Thompson, 2009.

7. Hernández-Valencia M, Hernández-Rosas M, Zárate A. Atención de la resistencia a la insulina en el síndrome de ovarios poliquísticos. Ginecol Obstet Mex 2010;78(11):612-616.

8. Spandorfer S, Davis OK, Rosenwaks Z. Síndrome del ovario poliquístico. La conexión metabólica con la resistencia a la insulina. En: Parrilla JJ, Delgado JL, Abad L, editores. Reproducción humana. 2a ed. McGraw-Hill Interamericana, 2002;171-174.

9. Velázquez EM, Acosta A, Mendoza SG. Menstrual ciclycity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392-395.

10. Legro RS, Barnhart HX, Schlaff WD, Carr BR, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356(6):551-566.

11. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75(1):46-52.

12. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89(3):505-522.